

# NYRx BLTG Program Update

---

## What Pharmacy Providers and Prescribers Need to Know

Effective **December 14, 2023**, the following changes will be made to the Dispense Brand Name Drug When Less Expensive Than the Generic Program:

- **Advair HFA<sup>®</sup>, Dymista<sup>®</sup>, Pennsaid<sup>®</sup> pump, Ritalin LA<sup>®</sup>, Vyvanse<sup>®</sup> capsule, Vyvanse<sup>®</sup> chewable tablet, and Xopenex HFA<sup>®</sup>** will be **ADDED** to the program.
- **Concerta<sup>®</sup>, Ciprodex<sup>®</sup>, and Viibryd<sup>®</sup>** will be **REMOVED** from the program.

In conformance with State Education Law, a pharmacist shall dispense a less expensive, therapeutically equivalent drug containing the same active ingredients, dosage form, and strength as the drug prescribed/ordered. This includes substituting the brand name drug when NYRx has determined it to be the less expensive alternative for the patient. Brand name drugs included in this program:

- Do not require “Dispense as Written” (DAW) or “Brand Medically Necessary” on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

## Important Billing Information

Pursuant to this program, prescription claims submitted to the Medicaid program **do not require** the submission of a DAW Product Selection Code of “1”; Pharmacies should **submit DAW code 9** (Substitution Allowed by Prescriber but Plan Requests Brand). Pharmacies will receive an NCPDP reject response of “22” which means missing/invalid DAW code if other DAW codes are submitted. The only exception to this is DAW code “1” and “Brand Medically Necessary” on the prescription.

For a complete list, see [NYRx BLTG Program Brand Name Drugs](#) on the next page.

## NYRx BLTG Drugs

NYRx BLTG Program Brand Name Drugs*		
Advair Diskus®	Glumetza®	Renvela® tablet
<b>Advair HFA®</b>	Kazano®	Restasis®
Alphagan P® 0.15%	Kitabis® Pak	Retin-A® cream
Amitiza®	Kombiglyze® XR	<b>Ritalin LA®</b>
Apriso®	Lialda®	Spiriva® HandiHaler®
Azopt™	Nesina®	Symbicort®
Bethkis®	Nexavar®	Tegretol® suspension
Cellcept® suspension	NuvaRing®	Tegretol® XR
Combigan®	Onglyza®	Trileptal® suspension
Copaxone® 20mg SQ	Oseni®	Vascepa®
Daytrana®	<b>Pennsaid® pump</b>	Ventolin® HFA
Depakote® Sprinkle	Pentasa®	<b>Vyvanse® capsule</b>
Dexilant®	Pradaxa®	<b>Vyvanse® chewable tablet</b>
<b>Dymista®</b>	Protonix® suspension	<b>Xopenex HFA®</b>
Epipen	Pylera®	Zegerid® Rx
Epipen JR	Rapamune® solution	
Flovent® HFA	Renvela® powder pack	

\* This list is subject to change. For the most recent updates, see the [Brand Less than Generic Program Updates](#).

\* Drugs in this program may be subject to prior authorization requirements of other pharmacy programs.

## Resources

- [NYRx Brand Less Than Generic Program](#)
- [NYRx Education & Outreach Website](#)
- [NYRx Pharmacy Program Preferred Drug List](#)

## Contact Information

The NYRx Education & Outreach Call Center is available at 833-967-7310 from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.